DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. “Our team continues to be very disciplined about executing our plans and is making strong progress advancing our clinical stage PBGENE-HBV program whil
Related Questions
What is the status of the ARCUS® platform development and any upcoming milestones or trials?
How much progress was made on the PBGENE‑HBV program, and what are the next clinical milestones?
What is the current burn rate and runway given the reported cash position?
How does the Q2 2025 performance compare to the same period in the previous year and to analyst expectations?
Are there any competitive threats or market dynamics highlighted that could affect Precision BioSciences' positioning?
What potential impact could these results and updates have on the stock’s valuation and price movement?
What were the key financial metrics (revenue, net loss, cash balance) reported for Q2 2025?
Did the company disclose any regulatory updates or interactions with the FDA that could impact timelines?
Are there any new partnership or licensing agreements announced that could affect future cash flows?
Did Precision BioSciences provide any updated guidance for future quarters or the full year?